keyword
MENU ▼
Read by QxMD icon Read
search

Ankylosing spondyloarthritis

keyword
https://www.readbyqxmd.com/read/29350332/sleep-in-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis-associations-with-disease-activity-gender-and-mood
#1
Alison Wadeley, Emily Clarke, Shaaron Leverment, Raj Sengupta
The study aims were to assess the prevalence of good or poor sleep in a cohort of axial spondyloarthritis patients and to investigate its correlation with a range of objectively and subjectively measured variables in order to develop a model for distinguishing good from poor sleepers. Five hundred ninety-eight patients with ankylosing spondylitis and 61 with non-radiographic axial spondyloarthritis completed the Jenkins Sleep Evaluation Questionnaire. Measures of disease activity, mobility, function, mood, fatigue, quality of life, work productivity, night-time pain and general health were gathered...
January 19, 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29343996/does-hla-b27-status-influence-ankylosing-spondylitis-phenotype
#2
REVIEW
Amal Akassou, Youssef Bakri
The association of HLA-B27 with ankylosing spondylitis (AS) remains as one of the intriguing models that could exist between a molecule and human disease in medicine. Although it was reported in 1973, its contribution to AS and related spondyloarthritis continues to be a major challenge for scientific community. It is important to understand its etiopathogenic mechanism and its functions in these diseases. Although the diagnostic and prognostic roles of HLA-B27 in AS are still debated, there is an increasing interest for HLA-B27-based effects especially in HLA-B27(+) patients with AS...
2018: Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders
https://www.readbyqxmd.com/read/29343510/limited-radiographic-progression-and-sustained-reductions-in-mri-inflammation-in-patients-with-axial-spondyloarthritis-4-year-imaging-outcomes-from-the-rapid-axspa-phase-iii-randomised-trial
#3
Désirée van der Heijde, Xenofon Baraliakos, Kay-Geert A Hermann, Robert B M Landewé, Pedro M Machado, Walter P Maksymowych, Owen R Davies, Natasha de Peyrecave, Bengt Hoepken, Lars Bauer, Tommi Nurminen, Juergen Braun
OBJECTIVES: To report 4-year imaging outcomes in the RAPID-axSpA (NCT01087762) study of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), treated with certolizumab pegol (CZP). METHODS: This phase III, randomised trial was placebo-controlled and double-blind to week 24, dose-blind to week 48 and open-label to week 204. Patients fulfilling the Assessment of Spondyloarthritis International Society (ASAS) axSpA criteria with active disease were stratified (AS/nr-axSpA) according to the modified New York (mNY) criteria at randomisation...
January 17, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29342471/extra-articular-manifestations-and-burden-of-disease-in-patients-with-radiographic-and-non-radiographic-axial-spondyloarthritis
#4
Kemal Erol, Kevser Gok, Gizem Cengiz, Gamze Kilic, Erkan Kilic, Salih Ozgocmen
OBJECTIVE: Although the prevalence of peripheral and extra-articular disease in ankylosing spondylitis (AS) has been assessed in many studies, data on non-radiographic axial spondyloarthritis (nr-axSpA) is scanty. The aim of this study was first, to compare radiographic-axSpA/AS (r-axSpA/AS) and nr-axSpA concerning peripheral arthritis and extra-articular manifestations (EAMs), and second, to assess potential differences between patient subgroups with or without EAMs regarding disease burden...
January 16, 2018: Acta Reumatológica Portuguesa
https://www.readbyqxmd.com/read/29329443/bone-formation-in-ankylosing-spondylitis-during-anti-tumour-necrosis-factor-therapy-imaged-by-18f-fluoride-positron-emission-tomography
#5
Stefan T G Bruijnen, Nicki J F Verweij, Leonie M van Duivenvoorden, Nathalie Bravenboer, Dominique L P Baeten, Christiaan J van Denderen, Irene E van der Horst-Bruinsma, Alexandre E Voskuyl, Martijn Custers, Peter M van de Ven, Joost C J Bot, Bouke J H Boden, Adriaan A Lammertsma, Otto S H Hoekstra, Pieter G H M Raijmakers, Conny J van der Laken
Objectives: Excessive bone formation is an important hallmark of AS. Recently it has been demonstrated that axial bony lesions in AS patients can be visualized using 18F-fluoride PET-CT. The aim of this study was to assess whether 18F-fluoride uptake in clinically active AS patients is related to focal bone formation in spine biopsies and is sensitive to change during anti-TNF treatment. Methods: Twelve anti-TNF-naïve AS patients [female 7/12; age 39 years (SD 11); BASDAI 5...
January 9, 2018: Rheumatology
https://www.readbyqxmd.com/read/29303699/implication-of-osteoprotegerin-and-sclerostin-in-axial-spondyloarthritis-cardiovascular-disease-study-of-163-spanish-patients
#6
Fernanda Genre, Javier Rueda-Gotor, Sara Remuzgo-Martínez, Alfonso Corrales, Begoña Ubilla, Verónica Mijares, Carlos Fernández-Díaz, Virginia Portilla, Ricardo Blanco, José Luis Hernández, Javier Llorca, Raquel López-Mejías, Miguel Angel González-Gay
OBJECTIVES: Due to the high incidence of cardiovascular disease in axial spondyloarthritis (axSpA), the search of potential biomarkers that may help to identify patients with high cardiovascular risk is of main importance. Therefore, in this study we assessed the implication of osteoprotegerin (OPG) and sclerostin (SCL), two biomarkers associated with cardiovascular disease and bone metabolism, in the clinical spectrum and atherosclerotic disease of patients with axSpA. METHODS: OPG and SCL serum levels were determined in 163 axSpA Spanish patients (119 ankylosing spondylitis and 44 non-radiographic axSpA) and 63 healthy controls by enzyme-linked immunosorbent assay...
December 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29299630/stability-of-fatigue-pain-patient-global-assessment-and-the-bath-ankylosing-spondylitis-functional-index-basfi-in-spondyloarthropathy-patients-with-stable-disease-according-to-the-bath-ankylosing-spondylitis-disease-activity-index-basdai
#7
Ole Rintek Madsen
The study objective was to examine natural variation of the patient-reported outcome measures fatigue, pain, patient global assessment (PaGl) and the Bath Ankylosing Spondylitis Functional Index (BASFI) in patients with stable axial spondyloarthropathy (ax-SpA) defined on the basis of the Bath Spondylitis Ankylosing Disease Activity Index (BASDAI). 107 TNF-inhibitor treated stable ax-SpA patients were identified in the Danish rheumatology registry (DANBIO). According to the Assessment of SpondyloArthritis international Society (ASAS) response criteria, stable disease was defined as a change in BASDAI < 20 between two consecutive visits...
January 3, 2018: Rheumatology International
https://www.readbyqxmd.com/read/29290076/risk-of-serious-infections-in-biological-treatment-of-patients-with-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis-a-meta-analysis
#8
Sen Wang, Qian He, Zongwen Shuai
The objective of the study is to quantitatively assess the risk of serious infections in patients with axial spondyloarthritis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) treated by biologics enrolled in randomized controlled trials (RCTs). A systematic literature searches of MEDLINE (via PubMed), EMBASE, the Cochrane Library and abstracts archives of the annual scientific meetings of both the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) was conducted through October 2015...
December 30, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/29278210/biologics-in-inflammatory-and-immunomediated-arthritis
#9
Michele Maria Luchetti, Devis Benfaremo, Armando Gabrielli
BACKGROUND: Biologic drugs, introduced in clinical practice almost twenty years ago, represent nowadays a prominent treatment option in patients with chronic inflammatory arthritis, such as Rheumatoid Arthritis, Psoriatic Arthritis and Spondyloarthritis, that include ankylosing spondylitis and non-radiographic axial spondyloarthritis. METHODS: Several compounds targeting different pathways have been marketed and approved for the treatment of inflammatory arthritis, with a significant impact on the clinical outcomes and the natural history of the diseases...
December 26, 2017: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/29273067/efficacy-safety-and-tolerability-of-secukinumab-in-patients-with-active-ankylosing-spondylitis-a-randomized-double-blind-phase-3-study-measure-3
#10
Karel Pavelka, Alan Kivitz, Eva Dokoupilova, Ricardo Blanco, Marco Maradiaga, Hasan Tahir, Luminita Pricop, Mats Andersson, Aimee Readie, Brian Porter
BACKGROUND: Secukinumab, an anti-interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) in two phase 3 studies (MEASURE 1 and MEASURE 2). Here, we present 52-week results from the MEASURE 3 study assessing the efficacy and safety of secukinumab 300 and 150 mg subcutaneous maintenance dosing, following an intravenous loading regimen. METHODS: A total of 226 patients were randomized to intravenous secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous secukinumab 300 mg (IV-300 mg) or 150 mg (IV-150 mg) every 4 weeks, or matched placebo...
December 22, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29273055/nonradiographic-axial-spondyloarthritis-clinical-and-therapeutic-relevance
#11
REVIEW
Nilasha Ghosh, Eric M Ruderman
Current classification criteria for axial spondyloarthritis (axSpA) provide for the inclusion of patients with a wide range of presentations and manifestations. While not considered a formal subclassification, patients are often divided into radiographic or nonradiographic axSpA based on the presence or absence of radiographic sacroiliitis. This review will focus on nonradiographic axSpA and will discuss clinical manifestations of disease that distinguish, or in many cases do not distinguish, this entity from other individuals with axSpA...
December 22, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29259045/risk-of-cardiac-rhythm-disturbances-and-aortic-regurgitation-in-different-spondyloarthritis-subtypes-in-comparison-with-general-population-a-register-based-study-from-sweden
#12
Karin Bengtsson, Helena Forsblad-d'Elia, Elisabeth Lie, Eva Klingberg, Mats Dehlin, Sofia Exarchou, Ulf Lindström, Johan Askling, Lennart T H Jacobsson
OBJECTIVES: To describe the incidence of atrioventricular (AV) block II-III, atrial fibrillation (AF), pacemaker implantation (PM) and aortic regurgitation in patients with ankylosing spondylitis (AS), undifferentiated spondyloarthritis (uSpA) and psoriatic arthritis (PsA) compared with the general population (GP) and with each other. METHODS: A prospective nationwide study with cohorts of patients with AS (n=6448), PsA (n=16 063) and uSpA (n=5190) and a GP (n=2 66 435) cohort, identified in 2001-2009 in the Swedish National Patient and Population registers...
December 19, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29247154/safety-and-efficacy-of-golimumab-administered-intravenously-in-adults-with-ankylosing-spondylitis-results-through-week-28-of-the-go-alive-study
#13
Atul Deodhar, John D Reveille, Diane D Harrison, Lilianne Kim, Kim-Hung Lo, Jocelyn H Leu, Elizabeth C Hsia
OBJECTIVE: To evaluate the safety and efficacy of intravenous golimumab (GOL) in patients with active ankylosing spondylitis (AS). METHODS: In a phase III, randomized, double-blind, placebo (PBO)-controlled trial, 208 patients were randomized (1:1) to intravenous (IV) infusions of GOL 2 mg/kg (n = 105) at weeks 0, 4, 12, and every 8 weeks, or PBO (n = 103) at weeks 0, 4, and 12, with crossover to GOL at Week 16. The primary endpoint was ≥ 20% improvement from baseline in the Assessment of Spondyloarthritis International Society Criteria (ASAS20) at Week 16...
December 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29240803/bone-edema-on-magnetic-resonance-imaging-is-highly-associated-with-low-bone-mineral-density-in-patients-with-ankylosing-spondylitis
#14
Danmin Wang, Zhiduo Hou, Yao Gong, Subiao Chen, Ling Lin, Zhengyu Xiao
OBJECTIVE: This study aimed to assess the relationship between bone marrow edema (BME) on magnetic resonance imaging (MRI) and bone mineral density (BMD) in patients with ankylosing spondylitis (AS). METHODS: The study included 333 patients with AS who underwent BMD measurements and axial MRI. Additionally, 106 normal controls were included. The modified New York criteria were used as the classification criteria of AS. Clinical, laboratory, and imaging data were collected and analyzed...
2017: PloS One
https://www.readbyqxmd.com/read/29227352/epidemiology-of-axial-spondyloarthritis-an-update
#15
Runsheng Wang, Michael M Ward
PURPOSE OF REVIEW: To provide an update of the prevalence and incidence of axial spondyloarthritis in the general population and in patients with spondyloarthritis-related conditions, environmental risk factors for ankylosing spondylitis, progression from nonradiographic axial spondyloarthritis to ankylosing spondylitis, mortality, and risks for cardiovascular events in patients with ankylosing spondylitis. RECENT FINDINGS: Increasingly, administrative healthcare data have been used to study disease frequency and outcomes...
December 8, 2017: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/29217947/coexistence-of-peripheral-spondyloarthritis-and-familial-adenomatous-polyposis-a-rare-case-report-with-treatment-contradictions-and-review-of-the-literature
#16
Berna Urkmez, Muge Kepekci, Sevde Ozer Posul, Aylin Rezvani
Background: The coexistence of familial adenomatous polyposis and spondyloarthritis is rarely defined in literature. The primary aim of this presentation is to report a development of peripheral arthritis in 3 years following colon surgery with the diagnosis of familial adenomatous polyposis (FAP). The secondary aim is to discuss the challenge of in treatment of refractory arthritis, which needs to be treated with biologics. However, it is not yet known well about their safety on patients who have risks for cancer development...
July 2017: Ethiopian Journal of Health Sciences
https://www.readbyqxmd.com/read/29202535/-the-safety-and-efficacy-of-golimumab-in-treatment-of-25-patients-with-active-ankylosing-spondylitis
#17
H Ma, F Sun, Y M Zhang, H Zhang, J Zhu, X H Deng, J L Zhang, F Huang
Objective: To evaluate the efficacy and safety of golimumab in patients with active ankylosing spondylitis (AS). Methods: This was a randomized, double-blind, placebo-controlled trial. The subjects were randomized to receive either golimumab 50mg subcutaneously or placebo every 4 weeks. Patients in both groups received golimumab 50mg from week 24 to week 48. The primary endpoint was the proportion of at least 20% improvement in the Assessment of Spondyloarthritis International Society (ASAS20) at week 14. The secondary endpoints included at least 40% improvement in the Assessment of Spondyloarthritis International Society (ASAS40), ASAS partial-remission, Bath AS functional index, Bath AS disease activity index, Bath AS metrology index, enthesitis index and Jenkins sleep evaluation questionnaire...
December 1, 2017: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/29200018/the-diagnostic-and-prognostic-role-of-interleukin-12b-and-interleukin-6r-gene-polymorphism-in-patients-with-ankylosing-spondylitis
#18
Wen-Feng Ruan, Jiang-Tao Xie, Qi Jin, Wen-Da Wang, An-Song Ping
OBJECTIVES: Interleukin 23 (IL-23) pathway and IL-1 cluster genes play prominent role in the etiopathology of ankylosing spondylitis (AS). The aim of this study was to investigate the diagnostic and prognostic role of 5 single-nucleotide polymorphisms related to IL-23 pathway and IL-1 cluster genes in AS patients. METHODS: Four hundred thirty-one patients with AS and 206 age- and sex-matched healthy controls were recruited in this prospective cohort study. Five potential single-nucleotide polymorphisms (IL-23R [rs11209026], IL-12B [rs6871626], TYK2 [rs6511701], IL-6R [rs4129267], and IL-1R2 [rs2192752]) related to IL-23 pathway and IL-1 cluster genes by analyzing previous studies were genotyped...
December 1, 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/29197633/spondyloarthritis-features-in-zymosan-induced-skg-mice
#19
Hyemin Jeong, Eun-Kyung Bae, Hunnyun Kim, Dong Hui Lim, Tae-Young Chung, Jaejoon Lee, Chan Hong Jeon, Eun-Mi Koh, Hoon-Suk Cha
OBJECTIVES: Spondyloarthritis (SpA) encompasses a group of disorders including ankylosing spondylitis, psoriatic arthritis, reactive arthritis, and enteropathic arthritis. SpA pathogenesis is still not well understood. Animal models are important for studying disease mechanisms and identifying new therapeutic agents. Recently, a β-glucan-induced SKG mouse was used as an animal model for SpA. The aim of this study was to evaluate the clinical and molecular characteristics of a zymosan-induced SKG mouse...
November 29, 2017: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/29195024/tuberculosis-risk-in-ankylosing-spondylitis-other-spondyloarthritis-and-psoriatic-arthritis-in-sweden-a-population-based-cohort-study
#20
Mirjam K de Vries, Elizabeth V Arkema, Jerker Jonsson, Judith Bruchfeld, Lennart Th Jacobsson, Johan Askling
OBJECTIVES: Rheumatoid arthritis (RA) is a risk factor for tuberculosis (TB), particularly following treatment with biologicals. Since these therapies are increasingly used in ankylosing spondylitis (AS), other types of spondyloarthritis (SpA) and psoriatic arthritis (PsA), we investigated the corresponding TB risks in these patients. METHODS: We identified individuals with AS/SpA/PsA, and non-AS/SpA/PsA comparators by linking Swedish national Patient, Population, TB and Rheumatology registers, and followed them for TB occurrence...
December 1, 2017: Arthritis Care & Research
keyword
keyword
100428
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"